Members of the United States House of Representatives are anticipated to vote this week (perhaps as earl as Tuesday night) on a series of amendments to a Justice Department spending bill. These amendments seek to limit the federal government’s intrusion in states that have regulated various aspects of marijuana production and access.
Specifically, Representatives Tom McClintock (R-CA) and Jared Polis (D-CO) are introducing an amendment intended to halt the federal prosecution of individuals involved in marijuana-related activities that are in compliance with the laws of their states. Last year, Congressional members approved an amendment to the DOJ funding bill that restricted the Department from interfering in activities specific to state medical marijuana programs. (That measure is also up for re-authorization; to learn more click here.) This year’s McClintock/Polis amendment is broader in its scope as it seeks to halt Justice Department interference among individuals and businesses engaged in state-compliant transactions particular to both the medical or recreational use of cannabis.
Please call your US Representative today via NORML’s Take Action Center here to support the McClintock/Polis amendment. Let them know that this amendment is supported by a majority of voters. According to a 2015 nationwide Pew Research poll, 59 percent of Americans agree that the government should not enforce federal marijuana laws in states that allow its use. Majorities of both Democrats and Republicans endorse this position.
Twenty-three states now permit the medical use of cannabis, while four states now regulate the plant’s production and sale to all adults. Tell Congress that federal officials should not stand in the way of these state policies and to vote ‘yes’ on the McClintock/Polis amendment.
You can also e-mail your House member and tell them to vote ‘yes’ on the McClintock/Polis amendment by clicking here.
The 2015 state legislative session has been the busiest on record.
State lawmakers have debated nearly 100 different marijuana law reform bills this session and some 60 bills remain pending.
NORML’s Take Action Center here provides you with the ability to track pending legislation in your state and to contact your elected officials and urge them to support marijuana law reform.
So far this legislative session, some 65,000 letters have been sent by NORML members to their elected officials in support of pending legislation. These efforts are paying dividends.
Below are some examples of pending legislation that need your support:
Delaware: Legislation to decriminalize minor marijuana offenses has passed committee and awaits a House floor vote. Take action here.
Hawaii: House and Senate lawmakers have approved legislation permitting medical cannabis production facilities and dispensaries. The measure now awaits the Governor’s signature. Take action here.
Illinois: Marijuana decriminalization legislation passed the House and now awaits action on the Senate floor. Take action here.
Minnesota: Legislation to legalize hemp farming has passed the House and now awaits action from the Senate. Take action here.
Missouri: Legislation establishing a licensed hemp cultivation program has been passed by the House and now awaits a vote on the Senate floor. Take action here.
New Hampshire: House lawmakers voted 3 to 1 to decriminalize marijuana possession offenses. The bill now awaits Senate action. Take action here.
Texas: Legislation to remove marijuana-related offenses from the Texas criminal code has passed out of committee and now awaits action from the House of Representatives. Take action here. Separate legislation decriminalizing marijuana possession offenses has also passed out of committee and awaits further House action. Take action here.
Additional legislation seeking to legalize the adult use and retail sale of cannabis remains pending in over a dozen states, while decriminalization and medical marijuana measures are pending in nearly 20 others. For a full listing of pending legislation and approved legislation, visit NORML’s Take Action Center here.
Marijuana law reform legislation is presently pending in over 30 states. Is your state one of them? Visit NORML’s online ‘Take Action Center’ here to find out.
By clicking this link, you will have access to up-to-date bill status information. You can also quickly contact your elected officials and urge their support for these reforms with just one click.
Right now, nearly 20 states — including Connecticut, Florida, Illinois, Maryland, Massachusetts, Pennsylvania, Rhode Island, Texas, and Vermont — are debating measures to legalize the adult use and sale of the plant.
Click HERE to view NORML’s full list of pending state and federal legislation.
Get active; get NORML.
Please join NORML on May 20/21 in Washington, D.C. to lobby Congress for passage of cannabis law reform legislation pending before it.
You’ve probably seen by now the historically important bill to reform medical cannabis laws introduced in the U.S. Senate. There has never been a more exciting and receptive time to be a cannabis law reform activist in America with this political backdrop:
- 35 states have passed medical cannabis-related legislation (in 23 of these states patients have functional access to the medicine and legal protections)
- 17 states have decriminalized the possession of cannabis for adults
- 4 states have legalized the cultivation and sale of cannabis (Washington, D.C. has de-penalized the possession and use of cannabis for adults; allows limited home cultivation; no sales)
- Every national poll, including the oldest social survey data set, now indicate a majority of Americans no longer favor cannabis prohibition.
It’s indisputable. Cannabis law reform in America is happening in our lifetimes.
By the time the NORML Legislative Fly-In convenes in late May, as many as 20 reform bills will have been introduced for us to rally around in our lobbying efforts–and with the new Senate bill, for the first time since the late 1970s, there is good reason to lobby the Senate as hard as the House.
Also, and of great importance in placing upward political pressure on elected members of Congress and their staff, are the nearly 75 state legislative bills around the country that are now debating cannabis law reform measures–ranging from medical access to industrial hemp to decriminalization to legalization.
This year upwards of half the states’ legislatures are looking at dozens of reform bills and this clearly positively impacts Congress to see these needed socio-legal reforms bubbling up from their home states and regions.
For many in Congress, they know the political writing is on the wall for the federal prohibition on cannabis commerce to survive much longer.
Let’s help make their jobs easier by showing them the necessary public support to hasten cannabis law reforms at the federal level.
Lastly, there is a strong possibility that we’re going to add another event to the program, in conjunction with High Times…and featuring a famous TV and movie personality who has expressed strong interest in getting involved with the public discussion about cannabis law reform. TBA.
NORML members and supporters get first shot at the low early bird pricing of $50/person.
Also, there are sponsorship opportunities as well for cannabis-related businesses, services and organizations.
Below is a brief breakdown of lodging options for the Conference.
Thanks in advance and hope to see you at the height of Spring in the nation’s capital, being an active participant in an historic public advocacy effort to once and for all end cannabis prohibition.
-Allen St. Pierre
NORML / NORML Foundation
Most of us were caught off-guard by the rush of states this year that approved the limited use of CBD-only marijuana extracts because these traditionally conservative states had heretofore rejected the medical use of marijuana. So it seems worth a moment to consider how this occurred, and what it means on a grander scale.
But first, a little recent history.
Throughout this year’s state legislative season, a total of 10 states enacted laws seeking to provide limited access to medical marijuana products that contain high levels of CBD and virtually no THC for qualified, typically pediatric patients suffering from severe and disabling seizures: Alabama, Florida, Iowa, Kentucky, Mississippi, Missouri, South Carolina, Tennessee, Utah and Wisconsin.
On one level, this unexpected embrace of the medicinal qualities of marijuana by states that previously rejected the concept must be seen as a favorable development. These serendipitous adoptions reflect a degree of compassion not obvious in the previous legislative debates in those states.
But it is far from certain that these laws will actually help the young patients they are intended to help.
First, such products are primarily only available in a handful of states like California and Colorado and none of these new state laws create a viable in-state supply source for such products. Further, even if a patient from out-of-state could find these products in California or Colorado, it would be a violation of federal law (and also likely state law) to take the medicine back to their home state.
And while some of these laws attempt to establish CBD research projects at their major universities or research hospitals, recent experience demonstrates that few universities or research hospitals are willing to enter this confusing field while marijuana remains a federal crime, and those that may be willing to take the bait will face a steep and long learning curve before the first patient will have high-CBD extracts available.
This legislative rush to CBD-only extracts also suggests (1) the degree to which elected officials are influenced by popular media, (2) their willingness to pick and choose the science they like (while ignoring the science they do not), and (3) the strong puritanical impulse that remains a factor with many elected officials.
And it all relates to the “Gupta Effect”. When CNN’s Dr. Sanjay Gupta’s report highlighting how high-CBD marijuana products control debilitating seizures among children suffering from Dravet’s syndrome (the most severe form of childhood epilepsy) went public, few Americans had even heard of cannabidiol. Most people were familiar with THC (tetrahydrocannabinol), the primary psychoactive ingredient in marijuana that principally accounts for the “high” that marijuana smokers enjoy, but had zero idea that CBD even existed.
Dr. Gupta, who had previously uncritically accepted the federal government’s consistent claim that marijuana had no legitimate medical use, when confronted with actual children whose lives had been transformed following their use of high-CBD marijuana extracts, understandably felt misled by the government’s anti-marijuana propaganda, and went public with two special programs introducing the importance of high-CBD extracts in reducing or eliminating seizures in these children.
In the second program Dr. Gupta made it clear that while CBD appeared to be the primary therapeutic ingredient for this class of patients, he also made the point that some level of THC was also required, because of what he termed the “entourage effect.” Without the THC, the CBD would either be less effective, or in some instances ineffective.
It’s embarrassing that so many of our elected officials would get their scientific understanding of the medical properties of marijuana from a popular television doctor, instead of conducting their own research into the available science, before moving legislation forward. But better they be motivated by a celebrity doctor than continue to ignore the benefits of medical marijuana altogether.
Of which there are a myriad.
The marijuana plant is one of the most studied biologically active substances of modern times. A search on PubMed, the repository for all peer-reviewed scientific papers, using the term “marijuana” yields nearly 20,000 scientific papers referencing the plant and/or its constituents, nearly half of which have been published just within the past decade. In addition, more than 100 controlled trials, involving thousands of subjects, have evaluated the safety and efficacy of cannabis and/or individual cannabinoids.
Most recently, a review of FDA-approved marijuana plant trials conducted by various California universities concluded, “Based on evidence currently available the Schedule I classification (for cannabis) is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking.” The best summary of this research can be found in the publication Emerging Clinical Applications for Cannabis and Cannabinoids, available on the NORML website. So the basic research is available for all who care to learn.
But few elected officials appear to be aware of this considerable body of science. Rather, the common refrain is to claim they cannot support the medical use of marijuana because the only evidence is “anecdotal”. These officials prefer to remain ignorant because it reinforces their preconceived notion that medical marijuana is a hoax perpetuated by those who simply wish to get “high”.
So what this latest rush to approve CBD-only marijuana products demonstrates, more than anything else, is the degree to which our public policy can frequently be influenced by a strong strain of puritanism that remains alive among our elected officials. If it feels good, it must be bad!
These many state legislators were willing to show some compassion by allowing the medical use of marijuana by these poor children suffering from multiple, disabling seizures, so long as the marijuana did not make them feel “high” (i.e., feel better!). These legislators are against pleasure, and if the use medical marijuana includes the feeling of pleasure, then it cannot be approved.
Excuse me, but is that not the purpose of using medicine when one is ill – to feel better?
Admittedly, for some of these puritans, the association of the word “high” with the use of marijuana may lie at the heart of the problem for them. Marijuana has long been demonized by conservatives, law enforcement, and many in the medical community, and that has spilled-over to the marijuana “high”.
If they understood that the marijuana “high” makes the user feel better, and that seriously ill patients almost always want (and need) to feel better, perhaps they could overcome their fear of medical marijuana. But for now at least, it is clear that in their view the marijuana “high”, like marijuana itself, is something to be avoided by responsible Americans, even if that precludes the use of medical marijuana by seriously ill patients.
It is time we moved beyond the notion that pleasure is bad, and stopped treating the marijuana “high” as something to be avoided, when it makes patient feel better. For them, feeling better and feeling high is often the same.